AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

George Budwell, PhD

TMFGBudwell

George Budwell, PhD, is a contributing Motley Fool biotechnology and technology analyst covering disruptive innovators in healthcare, defense, and artificial intelligence. He also writes on portfolio theory, dividend stocks, and value investing. Prior to The Motley Fool, George was a freelance medical and science writer and a consultant for several life sciences hedge funds. Earlier in his career, he was an evolutionary biologist and completed postdoctoral fellowships at Kyoto University and Illinois State University. He holds a doctorate in evolutionary biology from Tulane University and a bachelor’s degree from Loyola University.

Articles by George Budwell, PhD — Page 135

Sarepta Therapeutics: Discretion Is the Better Part of Valor

Nov 25, 2015 by George Budwell, PhD

Sarepta Therapeutics: Discretion Is the Better Part of Valor

Sarepta Therapeutics has been on an incredible bull run because of its experimental DMD therapy eteplirsen. Shareholders nevertheless need to consider taking one of two simple steps right now to protect themselves in case things reverse course in a hurry.

Here's Why Immunomedics' Stock Skyrocketed Higher in October

Nov 22, 2015 by George Budwell, PhD

Here's Why Immunomedics' Stock Skyrocketed Higher in October

Immunomedics' stock almost doubled in October. Here's why.

United Therapeutics' Stock Picked Up Steam in October: Time to Buy?

Nov 21, 2015 by George Budwell, PhD

United Therapeutics' Stock Picked Up Steam in October: Time to Buy?

A strong third-quarter earnings report propelled United Therapeutics' shares higher in October.

Better Dividend Stock: Amgen or AstraZeneca PLC?

Nov 20, 2015 by George Budwell, PhD

Better Dividend Stock: Amgen or AstraZeneca PLC?

Amgen and AstraZeneca are frequently near the top of many dividend investors' 'buy' lists because of their proven commitment to rewarding shareholders. Here's one Fool's take on which stock is the better choice right now.

Here's Why Advaxis' Stock Gained 11% in October

Nov 17, 2015 by George Budwell, PhD

Here's Why Advaxis' Stock Gained 11% in October

Despite a lack of good news, Advaxis' stock still rallied along with the broader cancer immunotherapy space last month. Can this trend continue moving forward?

Is This The Biggest Roadblock to a Pfizer-Allergan Merger?

Nov 17, 2015 by George Budwell, PhD

Is This The Biggest Roadblock to a Pfizer-Allergan Merger?

Pfizer's legacy products may get left out in the cold if the drugmaker goes through with a proposed merger with Botox-maker Allergan.

Is Vital Therapies' Stock Still A Buy After Gaining 90% in October?

Nov 17, 2015 by George Budwell, PhD

Is Vital Therapies' Stock Still A Buy After Gaining 90% in October?

Vital Therapies rebounded strongly in October after the company announced a new late-stage trial for its extracorporeal liver-assist device.

Here's Why Clovis Oncology's Stock Is Getting Pummeled Today

Nov 16, 2015 by George Budwell, PhD

Here's Why Clovis Oncology's Stock Is Getting Pummeled Today

Clovis Oncology's stock nosedives after a mid-cycle review of its experimental lung cancer drug.

Is Ziopharm Oncology's Stock a Buy After Gaining 23% in October?

Nov 11, 2015 by George Budwell, PhD

Is Ziopharm Oncology's Stock a Buy After Gaining 23% in October?

The biotech's stock rocketed higher in October. Should investors jump on this high-flying biotech stock right now?

Here's Why MannKind Corporation's Stock Is Crashing Today

Nov 11, 2015 by George Budwell, PhD

Here's Why MannKind Corporation's Stock Is Crashing Today

MannKind's shares continue to spiral downward on the growing fear that Sanofi is about to hit the eject button on Afrezza's marketing agreement.

Does Kite Pharma's Stock Still Have Room to Run After Climbing 19% in October?

Nov 10, 2015 by George Budwell, PhD

Does Kite Pharma's Stock Still Have Room to Run After Climbing 19% in October?

The immunotherapy company's stock jumped nearly 20% last month following positive media coverage of its experimental non-Hodgkin lymphoma treatment.

What Does 2016 Hold for This Closely-Watched Biotech ETF?

Nov 9, 2015 by George Budwell, PhD

What Does 2016 Hold for This Closely-Watched Biotech ETF?

Will the IBB return to its high flying ways in 2016 or will the debate over drug prices drag this popular ETF down?

Horizon Pharma's Stock Briefly Spikes on Investor Update

Nov 9, 2015 by George Budwell, PhD

Horizon Pharma's Stock Briefly Spikes on Investor Update

Horizon Pharma's stock briefly rises after management provides investors with a highly positive long-term outlook.

Horizon Pharma's Stock Bolts Higher on Strong Q3 Results

Nov 6, 2015 by George Budwell, PhD

Horizon Pharma's Stock Bolts Higher on Strong Q3 Results

Shares of Horizon Pharma shoot higher after the company crushes consensus for both earnings per share and revenue in the third quarter.

Here's Why Intersect ENT, Inc.'s Stock Cratered Today

Nov 5, 2015 by George Budwell, PhD

Here's Why Intersect ENT, Inc.'s Stock Cratered Today

Intersect ENT misses consensus on both earnings and revenue, sending its shares spiraling downwards today.

Diplomat Pharmacy's Stock Jumps On Strong Third Quarter Results

Nov 4, 2015 by George Budwell, PhD

Diplomat Pharmacy's Stock Jumps On Strong Third Quarter Results

Diplomat Pharmacy's shares rally on a strong third quarter earnings report.

Which Dividends Would Be Safest If Drug Prices Were Slashed Tomorrow?

Nov 2, 2015 by George Budwell, PhD

Which Dividends Would Be Safest If Drug Prices Were Slashed Tomorrow?

Healthcare stocks have been getting walloped because of the growing fear that drug prices may come tumbling down in the United States. Here's one Fool's look at some of the top names in the industry and how their dividends might fare in a worst-case scenario.

Is Inovio Pharmaceuticals a Late Bloomer?

Oct 30, 2015 by George Budwell, PhD

Is Inovio Pharmaceuticals a Late Bloomer?

Inovio Pharmaceuticals signed major research agreements with both AstraZeneca and Roche within the last two years, and it's now close to advancing its lead clinical candidate into a late-stage study. Is this biotech finally coming of age?

Here's Why Wall Street May Be Dead Wrong About AbbVie

Oct 27, 2015 by George Budwell, PhD

Here's Why Wall Street May Be Dead Wrong About AbbVie

The market has been thrashing AbbVie's stock this year, while Wall Street has continually come to the drugmaker's defense. Here's why Mr. Market may in fact be right in its pessimistic outlook.

BioDelivery Sciences International's Stock Jumps on FDA Approval

Oct 26, 2015 by George Budwell, PhD

BioDelivery Sciences International's Stock Jumps on FDA Approval

BioDelivery Sciences' shares push higher on the news that the FDA approved the chronic pain medicine Belbuca.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services